These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
139 related articles for article (PubMed ID: 15181975)
1. Comparison of mechanisms after post-hoc analyses of the drotrecogin alfa (activated) and antithrombin III trials in severe sepsis. Wiedermann CJ; Kaneider NC Ann Med; 2004; 36(3):194-203. PubMed ID: 15181975 [TBL] [Abstract][Full Text] [Related]
2. Biomarker response to drotrecogin alfa (activated) in children with severe sepsis: results from the RESOLVE clinical trial*. Dalton HJ; Carcillo JA; Woodward DB; Short MA; Williams MD Pediatr Crit Care Med; 2012 Nov; 13(6):639-45. PubMed ID: 22791090 [TBL] [Abstract][Full Text] [Related]
3. Benefit-risk assessment of drotrecogin alfa (activated) in the treatment of sepsis. De Backer D Drug Saf; 2007; 30(11):995-1010. PubMed ID: 17973539 [TBL] [Abstract][Full Text] [Related]
4. Drotrecogin alfa (activated) (recombinant human activated protein C) for the treatment of severe sepsis. Bernard GR Crit Care Med; 2003 Jan; 31(1 Suppl):S85-93. PubMed ID: 12544981 [TBL] [Abstract][Full Text] [Related]
5. Safety, pharmacokinetics, and pharmacodynamics of drotrecogin alfa (activated) in children with severe sepsis. Barton P; Kalil AC; Nadel S; Goldstein B; Okhuysen-Cawley R; Brilli RJ; Takano JS; Martin LD; Quint P; Yeh TS; Dalton HJ; Gessouron MR; Brown KE; Betts H; Levin M; Macias WL; Small DS; Wyss VL; Bates BM; Utterback BG; Giroir BP Pediatrics; 2004 Jan; 113(1 Pt 1):7-17. PubMed ID: 14702440 [TBL] [Abstract][Full Text] [Related]
6. Drotrecogin alfa (activated): a novel therapeutic strategy for severe sepsis. Pastores SM Postgrad Med J; 2003 Jan; 79(927):5-10. PubMed ID: 12566544 [TBL] [Abstract][Full Text] [Related]
7. Drotrecogin alfa: a second look. More clinical trials in severe sepsis: mostly negative results. Prescrire Int; 2007 Feb; 16(87):7-9. PubMed ID: 17323514 [TBL] [Abstract][Full Text] [Related]
8. Effect of factor V Leiden polymorphism in severe sepsis and on treatment with recombinant human activated protein C. Yan SB; Nelson DR Crit Care Med; 2004 May; 32(5 Suppl):S239-46. PubMed ID: 15118525 [TBL] [Abstract][Full Text] [Related]
9. Drotrecogin alfa (activated) administration across clinically important subgroups of patients with severe sepsis. Ely EW; Laterre PF; Angus DC; Helterbrand JD; Levy H; Dhainaut JF; Vincent JL; Macias WL; Bernard GR; Crit Care Med; 2003 Jan; 31(1):12-9. PubMed ID: 12544987 [TBL] [Abstract][Full Text] [Related]
10. Drotrecogin alfa (recombinant human activated protein C) for the treatment of severe sepsis. McCoy C; Matthews SJ Clin Ther; 2003 Feb; 25(2):396-421. PubMed ID: 12749504 [TBL] [Abstract][Full Text] [Related]
11. Drotrecogin alfa (activated) in the treatment of severe sepsis. Vincent JL Expert Rev Anti Infect Ther; 2006 Aug; 4(4):537-47. PubMed ID: 17009934 [TBL] [Abstract][Full Text] [Related]
12. New and emerging therapies for sepsis. Healy DP Ann Pharmacother; 2002 Apr; 36(4):648-54. PubMed ID: 11918516 [TBL] [Abstract][Full Text] [Related]
13. Pharmacology, clinical efficacy, and safety of drotrecogin alfa (activated). Rudis MI; Fish DN Pharmacotherapy; 2002 Dec; 22(12 Pt 2):182S-195S. PubMed ID: 12492225 [TBL] [Abstract][Full Text] [Related]
14. Predictors of hospital mortality for patients with severe sepsis treated with Drotrecogin alfa (activated). Micek ST; Isakow W; Shannon W; Kollef MH Pharmacotherapy; 2005 Jan; 25(1):26-34. PubMed ID: 15767217 [TBL] [Abstract][Full Text] [Related]
15. Extended evaluation of recombinant human activated protein C United States Trial (ENHANCE US): a single-arm, phase 3B, multicenter study of drotrecogin alfa (activated) in severe sepsis. Bernard GR; Margolis BD; Shanies HM; Ely EW; Wheeler AP; Levy H; Wong K; Wright TJ; Chest; 2004 Jun; 125(6):2206-16. PubMed ID: 15189943 [TBL] [Abstract][Full Text] [Related]
16. Readministration of drotrecogin alfa (activated) in an adult with severe sepsis. Scipione MR; Nogid B; Davanos E; DiGregorio RV Am J Health Syst Pharm; 2011 Sep; 68(18):1711-5. PubMed ID: 21880886 [TBL] [Abstract][Full Text] [Related]
18. Drotrecogin alfa (recombinant human activated protein C) in severe sepsis--a New Zealand viewpoint. Liang J; Streat S; Torrance J; Sleigh J; Freebairn R; Ramsay M N Z Med J; 2003 Sep; 116(1181):U586. PubMed ID: 14581969 [TBL] [Abstract][Full Text] [Related]
20. Estimate of the number of patients eligible for treatment with drotrecogin alfa (activated) based on differing international indications: post-hoc analysis of an inception cohort study in Australia and New Zealand. Finfer S; Felton T; Blundell A; Lipman J; Anaesth Intensive Care; 2006 Apr; 34(2):184-90. PubMed ID: 16617638 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]